NASDAQ:NTLA Intellia Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Intellia Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $21.28 +0.46 (+2.21 %) (As of 09/25/2020 12:00 AM ET) Add Compare Share Today's Range$20.68Now: $21.28▼$21.4850-Day Range$17.47MA: $20.47▼$23.5152-Week Range$9.18Now: $21.28▼$25.56Volume617,298 shsAverage Volume832,114 shsMarket Capitalization$1.25 billionP/E RatioN/ADividend YieldN/ABeta1.69 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria. Its ex vivo pipeline includes proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune diseases; partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells; and acute myeloid leukemia. Intellia Therapeutics, Inc. has collaboration agreement with Novartis Institutes for BioMedical Research, Inc.; Ospedale San Raffaele; Regeneron Pharmaceuticals, Inc.; and Caribou Biosciences, Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingIntellia Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $29.58, Intellia Therapeutics has a forecasted upside of 39.0% from its current price of $21.28.Amount of Analyst CoverageIntellia Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesIntellia Therapeutics has received 317 “outperform” votes. (Add your “outperform” vote.)Underperform VotesIntellia Therapeutics has received 286 “underperform” votes. (Add your “underperform” vote.)Community SentimentIntellia Therapeutics has received 52.57% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Intellia Therapeutics and other stocks. Vote “Outperform” if you believe NTLA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NTLA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldIntellia Therapeutics does not currently pay a dividend.Dividend GrowthIntellia Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Intellia Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $581,815.00 in company stock.Percentage Held by InsidersOnly 5.10% of the stock of Intellia Therapeutics is held by insiders.Percentage Held by Institutions91.79% of the stock of Intellia Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Intellia Therapeutics are expected to decrease in the coming year, from ($2.34) to ($2.98) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Intellia Therapeutics is -9.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Intellia Therapeutics is -9.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIntellia Therapeutics has a P/B Ratio of 3.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.38 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Diagnostic substances Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NTLA Previous Symbol CUSIPN/A CIK1652130 Webwww.intelliatx.com Phone857-285-6200Debt Debt-to-Equity Ratio0.05 Current Ratio7.55 Quick Ratio7.55Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$43.10 million Price / Sales29.00 Cash FlowN/A Price / Cash FlowN/A Book Value$5.52 per share Price / Book3.86Profitability EPS (Most Recent Fiscal Year)($2.11) Net Income$-99,530,000.00 Net Margins-228.87% Return on Equity-40.57% Return on Assets-31.24%Miscellaneous Employees211 Outstanding Shares58,741,000Market Cap$1.25 billion Next Earnings Date10/29/2020 (Estimated) OptionableOptionable $21.28 +0.46 (+2.21 %) (As of 09/25/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive NTLA News and Ratings via Email Sign-up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter. Intellia Therapeutics (NASDAQ:NTLA) Frequently Asked Questions How has Intellia Therapeutics' stock price been impacted by COVID-19 (Coronavirus)? Intellia Therapeutics' stock was trading at $12.72 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, NTLA shares have increased by 67.3% and is now trading at $21.28. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Intellia Therapeutics? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intellia Therapeutics in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Intellia Therapeutics. When is Intellia Therapeutics' next earnings date? Intellia Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, October 29th 2020. View our earnings forecast for Intellia Therapeutics. How were Intellia Therapeutics' earnings last quarter? Intellia Therapeutics Inc (NASDAQ:NTLA) announced its earnings results on Thursday, August, 6th. The company reported ($0.61) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.69) by $0.08. The business had revenue of $16.26 million for the quarter, compared to the consensus estimate of $9.52 million. Intellia Therapeutics had a negative return on equity of 40.57% and a negative net margin of 228.87%. The firm's quarterly revenue was up 46.3% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.56) earnings per share. View Intellia Therapeutics' earnings history. What price target have analysts set for NTLA? 7 equities research analysts have issued 1-year price objectives for Intellia Therapeutics' shares. Their forecasts range from $20.00 to $57.50. On average, they expect Intellia Therapeutics' stock price to reach $29.58 in the next year. This suggests a possible upside of 39.0% from the stock's current price. View analysts' price targets for Intellia Therapeutics. Who are some of Intellia Therapeutics' key competitors? Some companies that are related to Intellia Therapeutics include Neogen (NEOG), Heska (HSKA), Myriad Genetics (MYGN), Lantheus (LNTH), Meridian Bioscience (VIVO), Celldex Therapeutics (CLDX), Quotient (QTNT), Oxford Immunotec Global (OXFD), Aspira Women's Health (AWH), Vermillion (VRML), GeneNews (GNWSF), Nymox Pharmaceutical (NYMX), Riot Blockchain (RIOT), OncoCyte (OCX) and Biomerica (BMRA). View all competitors. What other stocks do shareholders of Intellia Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Intellia Therapeutics investors own include Editas Medicine (EDIT), Crispr Therapeutics (CRSP), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Square (SQ), Advanced Micro Devices (AMD), Intel (INTC), InVitae (NVTA) and QUALCOMM (QCOM). Who are Intellia Therapeutics' key executives? Intellia Therapeutics' management team includes the following people: Dr. John M. Leonard, Pres, CEO & Director (Age 62)Mr. Nessan Bermingham Ph.D., Founder & Member of Scientific Advisor Board (Age 46)Mr. José E. Rivera, Exec. VP & Gen. Counsel (Age 53)Ms. Rachel Haurwitz Ph.D., Co-Founder (Age 33)Mr. Andrew May Ph.D., Founder and Member of Scientific Advisor Board When did Intellia Therapeutics IPO? (NTLA) raised $85 million in an initial public offering on Friday, May 6th 2016. The company issued 5,000,000 shares at $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager. What is Intellia Therapeutics' stock symbol? Intellia Therapeutics trades on the NASDAQ under the ticker symbol "NTLA." Who are Intellia Therapeutics' major shareholders? Intellia Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (12.06%), Vanguard Group Inc. (7.25%), FMR LLC (2.74%), Point72 Asset Management L.P. (1.48%), Nuveen Asset Management LLC (0.75%) and Avidity Partners Management LP (0.71%). Company insiders that own Intellia Therapeutics stock include Andrew Schiermeier, John M Leonard and Jose E Rivera. View institutional ownership trends for Intellia Therapeutics. Which institutional investors are selling Intellia Therapeutics stock? NTLA stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Orbimed Advisors LLC, Jacobs Levy Equity Management Inc., AQR Capital Management LLC, Bank of America Corp DE, PNC Financial Services Group Inc., PNC Financial Services Group Inc., and WS Management Lllp. Company insiders that have sold Intellia Therapeutics company stock in the last year include John M Leonard, and Jose E Rivera. View insider buying and selling activity for Intellia Therapeutics. Which institutional investors are buying Intellia Therapeutics stock? NTLA stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., FMR LLC, Vanguard Group Inc., Avidity Partners Management LP, Artal Group S.A., Nuveen Asset Management LLC, Monashee Investment Management LLC, and Federated Hermes Inc.. View insider buying and selling activity for Intellia Therapeutics. How do I buy shares of Intellia Therapeutics? Shares of NTLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Intellia Therapeutics' stock price today? One share of NTLA stock can currently be purchased for approximately $21.28. How big of a company is Intellia Therapeutics? Intellia Therapeutics has a market capitalization of $1.25 billion and generates $43.10 million in revenue each year. The company earns $-99,530,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Intellia Therapeutics employs 211 workers across the globe. What is Intellia Therapeutics' official website? The official website for Intellia Therapeutics is www.intelliatx.com. How can I contact Intellia Therapeutics? Intellia Therapeutics' mailing address is 40 Erie Street Suite 130, Cambridge MA, 02139. The company can be reached via phone at 857-285-6200 or via email at [email protected] This page was last updated on 9/26/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
